Harrow launches next-generation compounded atropine formulations
Click Here to Manage Email Alerts
Eye care pharmaceutical company Harrow announced the launch of its next-generation compounded atropine formulations, which are now available at ImprimisRx, its compounding and mail-order pharmacy subsidiary.
According to a Harrow press release, the new formulations can be stored at room temperature for up to 180 days, contain no preservatives or boric acid and have a physiologic pH of 5.5. They have undergone validated testing for consistency, potency and stability.
“Our mission has always been to help our eye care professionals address their patients’ unmet needs and to make ophthalmic medications both accessible and affordable,” Mark L. Baum, chairman and CEO at Harrow, said in the release. “The availability of these innovative compounded atropine formulations is in keeping with our mission.
“We believe ophthalmologists, optometrists and the millions of Americans who may benefit from topical atropine therapy will appreciate the tremendous value these patent-pending formulations offer.”
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts